EUVIMEDEUVIMED entdecken
Crossref

Dynamic Changes in Circulating and Tissue Biomarkers and Therapeutic Response to HER2/PD-1 Dual Blockade in HER2-Positive Gastric Cancer

Yueyan Shi, Jie Zhang, Jianmei Gu, Wenjing Zhao, Guoxing Li, Xiaohua He

Digestion · 21.07.2026 · 1-13

DOI: 10.1159/000553654 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestion, online erschienen am 21.07.2026. Verfasst von Yueyan Shi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Nantong Tumor Hospital (Affiliated Tumor Hospital of Nantong University), Nantong, China. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

HER2-positive gastric adenocarcinoma demonstrates heterogeneous responses to dual HER2/PD-1 blockade therapy. This study investigated integrated circulating tumor DNA (ctDNA), protein biomarkers, and immune cell profiling for predicting treatment outcomes and monitoring therapeutic resistance.

Methods

This retrospective analysis included 72 patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma receiving anti-HER2 therapy plus PD-1 inhibitors. Serial blood samples underwent ctDNA sequencing, protein biomarker measurement, and flow cytometric immune cell characterization. Multivariable analysis identified independent predictors and developed an integrated biomarker model for patient stratification.

Results

Objective response rate was 40.3% with a median progression-free survival of 11.4 months. Sustained ctDNA suppression in 24 patients correlated with prolonged survival compared to early rebound patterns (p = 0.048). Co-occurring genomic alterations in EGFR, PIK3CA, MYC, and FGFR2 were detected in ctDNA and were associated with shorter progression-free survival. CD8+ T-cell increases and natural killer cell activity patterns differed between responders and nonresponders. Multivariable analysis identified composite immune score (HR: 0.58, p = 0.003), tumor stage (HR: 2.31, p < 0.001), and performance status as independent predictors. An exploratory integrated biomarker model stratified patients into risk categories of differing outcomes, although discrimination was modest (area under the curve: 0.65) and requires prospective validation.

Conclusion

Integrated ctDNA and immune biomarker monitoring may provide prognostic information for dual HER2/PD-1 blockade therapy. Serial molecular profiling enables early resistance detection and identifies evolutionary patterns that may inform therapeutic strategies, though prospective validation is required.

Schlagwörter

Stichwörter der Autor:innen

Biomarker dynamicsCirculating tumor DNAHER2-positive gastric cancerPD-1 inhibitorPrecision oncologyTrastuzumab

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Nantong Tumor Hospital (Affiliated Tumor Hospital of Nantong University), Nantong, China.
  • Department of Laboratory Medicine, Nantong Tumor Hospital (Affiliated Tumor Hospital of Nantong University), Nantong, China, jmgu1827@163.com.
  • Research Center, Nantong Tumor Hospital (Affiliated Tumor Hospital of Nantong University), Nantong, China.
  • Department of Surgery, Nantong Tumor Hospital (Affiliated Tumor Hospital of Nantong University), Nantong, China.

Zitieren

APA

Shi, Y., Zhang, J., Gu, J., Zhao, W., Li, G., & He, X. (2026). Dynamic Changes in Circulating and Tissue Biomarkers and Therapeutic Response to HER2/PD-1 Dual Blockade in HER2-Positive Gastric Cancer. Digestion, 1-13. https://doi.org/10.1159/000553654

Vancouver

Shi Y, Zhang J, Gu J, Zhao W, Li G, He X. Dynamic Changes in Circulating and Tissue Biomarkers and Therapeutic Response to HER2/PD-1 Dual Blockade in HER2-Positive Gastric Cancer. Digestion. 2026:1-13. doi:10.1159/000553654

BibTeX
@article{Shi2026,
  author = {Shi, Yueyan and Zhang, Jie and Gu, Jianmei and Zhao, Wenjing and Li, Guoxing and He, Xiaohua},
  title = {Dynamic Changes in Circulating and Tissue Biomarkers and Therapeutic Response to HER2/PD-1 Dual Blockade in HER2-Positive Gastric Cancer},
  journal = {Digestion},
  year = {2026},
  pages = {1--13},
  doi = {10.1159/000553654}
}
Kostenlos starten →